Aptevo Therapeutics Reports Third Quarter 2026 Financial Results
Aptevo Therapeutics (APVO) has released its financial results for the third quarter of 2026. The company reported a net loss of $6.5 million for the quarter, which represents an improvement compared to the $7.5 million net loss recorded during the same period in 2025. As of September 30, 2026, Aptevo's cash and cash equivalents stood at $8.3 million, a decrease from the $9.8 million reported at the end of the second quarter. The company also noted recent activity regarding the exercise of existing warrants, which generated $3 million in gross proceeds.

Tickers: $APVO
Topics: cash position net loss warrant exercise
Read the full article at Seeking Alpha
Part of the story Elah Holdings, Inc. Releases Third Quarter 2026 Financial Statements (8 articles)